Ruud Dobber
AstraZeneca
Ruud Dobber was appointed President and EVP, BioPharmaceuticals Business Unit at AstraZeneca in January 2019 and is responsible for US and Global product strategy and commercial delivery for Cardiovascular, Renal & Metabolism and Respiratory diseases. Prior to this, Ruud held the role of EVP, North America since August 2016. Ruud joined Astra in 1997 and has held various senior commercial and leadership roles, including as EVP, Europe, Regional Vice-President of AstraZeneca’s European, Middle East and African division, Regional Vice-President for the Asia Pacific region and Interim Executive Vice-Presid